News

June 12, 2019

Combining 2 Assessments of Breast Cancer Recurrence Risk May Help Guide Use of Adjuvant Chemotherapy

News

Adding an assessment of a woman’s clinical risk to Genomic Health‘s genomic test Oncotype DX to estimate the likelihood of breast cancer recurrence may spare more young women from having ... Read more

June 7, 2019

Long-term Data Continue to Support Perjeta Regimen for HER2-positive Metastatic Breast Cancer

News

End-of-study data from the CLEOPATRA trial supports the long-term efficacy of Genentech‘s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy for patients with previously untreated HER2-positive metastatic breast cancer. Patients on the ... Read more

June 5, 2019

New AI-based Model Outperforms Current Methods of Predicting Breast Cancer Risk

News

Scientists have created a new artificial intelligence (AI)-based model that outperforms current models at predicting the risks a woman has of developing breast cancer, and works equally well in white ... Read more

June 3, 2019

Chemo Resistance in TNBC Due to Molecular Changes That May Be Treatable, Study Suggests

News

Triple-negative breast cancer (TNBC) cells can become resistant to chemotherapy by temporarily turning on molecular pathways that protect the tumor, new research using mouse models and patient tumor samples uncovered. ... Read more

May 31, 2019May 31, 2019

Prestige’s HD201, a Biosimilar to Herceptin, Accepted for Review in Europe for HER2-positive BC

News

The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) submitted by Prestige BioPharma for HD201, its lead biosimilar to Genentech‘s Herceptin (trastuzumab). Like Herceptin, HD201 ... Read more

May 29, 2019May 29, 2019

FDA Approves Piqray-Faslodex Combo for Some Patients with Advanced Breast Cancer

News

Breast cancer patients in the U.S. who are receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-), and have mutated PIK3CA can now be treated with Novartis‘ Piqray (alpelisib) ... Read more

May 24, 2019

Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows

News

Keytruda (pembrolizumab), Merck‘s anti-PD-1 checkpoint blockade immunotherapy, failed to prolong the overall survival of patients with metastatic triple-negative breast cancer (TNBC) beyond that provided by chemotherapy agents, a Phase 3 ... Read more

May 22, 2019

Treatment Intensity Should Be Personalized in Women with HER2-positive Breast Cancer, Study Says

News

Personalized treatment intensity is crucial to the success of less toxic and demanding therapies for women with HER2-positive breast cancer, according to a spokesperson from the European Society for Medical ... Read more

May 20, 2019

Young Women More Likely to Face Aggressive BC Types, But Proper Treatment Improves Outcomes

News

Young women are more likely than older ones to be diagnosed with more aggressive forms of breast cancer, but their outcomes can be good if they follow recommended treatments. That ... Read more

May 15, 2019

Experimental Antibody Therapy Leads to Significant Responses in HER2-positive Breast Cancer, Phase 2 Trial Shows

News

Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial ... Read more